Gulf International Bank UK Ltd Sells 1,437 Shares of DexCom, Inc. (NASDAQ:DXCM)

Gulf International Bank UK Ltd decreased its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 4.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 30,638 shares of the medical device company’s stock after selling 1,437 shares during the period. Gulf International Bank UK Ltd’s holdings in DexCom were worth $2,053,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Empirical Finance LLC raised its stake in DexCom by 3.6% during the first quarter. Empirical Finance LLC now owns 13,221 shares of the medical device company’s stock worth $1,834,000 after acquiring an additional 462 shares in the last quarter. Envestnet Portfolio Solutions Inc. boosted its holdings in shares of DexCom by 2.3% in the 1st quarter. Envestnet Portfolio Solutions Inc. now owns 26,721 shares of the medical device company’s stock worth $3,706,000 after acquiring an additional 601 shares in the last quarter. Quantbot Technologies LP bought a new stake in DexCom during the 1st quarter worth approximately $853,000. Empowered Funds LLC increased its holdings in DexCom by 30.7% during the 1st quarter. Empowered Funds LLC now owns 5,518 shares of the medical device company’s stock valued at $765,000 after purchasing an additional 1,295 shares in the last quarter. Finally, SG Americas Securities LLC raised its position in DexCom by 104.9% in the 1st quarter. SG Americas Securities LLC now owns 77,926 shares of the medical device company’s stock valued at $10,808,000 after purchasing an additional 39,901 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have weighed in on DXCM shares. Baird R W cut shares of DexCom from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 26th. UBS Group decreased their price objective on DexCom from $163.00 to $95.00 and set a “buy” rating on the stock in a research report on Friday, July 26th. Royal Bank of Canada dropped their price objective on DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a report on Friday, October 25th. Oppenheimer reduced their target price on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a research note on Friday, October 25th. Finally, JPMorgan Chase & Co. boosted their price target on shares of DexCom from $75.00 to $85.00 and gave the stock a “neutral” rating in a research note on Friday, October 25th. Seven analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $104.59.

DexCom Trading Down 0.6 %

Shares of NASDAQ:DXCM opened at $68.61 on Thursday. The company’s fifty day simple moving average is $69.66 and its 200 day simple moving average is $94.30. The firm has a market cap of $26.80 billion, a price-to-earnings ratio of 41.08, a PEG ratio of 2.16 and a beta of 1.17. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00.

Insider Transactions at DexCom

In other DexCom news, EVP Sadie Stern sold 426 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $29,457.90. Following the sale, the executive vice president now owns 75,451 shares in the company, valued at approximately $5,217,436.65. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other DexCom news, EVP Sadie Stern sold 426 shares of DexCom stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $29,457.90. Following the sale, the executive vice president now directly owns 75,451 shares in the company, valued at approximately $5,217,436.65. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO Jacob Steven Leach sold 746 shares of the firm’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the transaction, the chief operating officer now owns 264,915 shares of the company’s stock, valued at $18,318,872.25. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. 0.30% of the stock is owned by insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.